Overview of U.S. Patent 4,359,578
U.S. Patent 4,359,578 was granted on November 16, 1982, to Schering Corporation for a method of treating hypercholesterolemia using a class of compounds, specifically hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, now widely known as statins. This patent represents one of the foundational patents in the statin class of cholesterol-lowering drugs.
Scope and Claims Analysis
Primary Claims
The core claims of Patent 4,359,578 encompass methods for decreasing cholesterol levels in mammals by administering specific HMG-CoA reductase inhibitors. The claims broadly cover:
- Administering compounds structurally related to the prototype, mevastatin.
- At effective doses to reduce serum cholesterol.
- The treatment method is applicable for hypercholesterolemia indications.
The claims specify the use of certain specific statin compounds, including intermediate and final forms, with particular note to mevastatin (compactin), though they are written to encompass structurally similar derivatives.
Scope Interpretation
The scope includes:
- Methods for lowering serum cholesterol using specific HMG-CoA reductase inhibitors.
- The compounds’ structural class, primarily based on the lactone ring structure characteristic of statins.
- Usage in mammals, notably humans, for hypercholesterolemia treatment.
However, the claims are limited in scope to the compounds described and their specific methods of administration and application for cholesterol reduction. The patent does not claim the compounds per se as novel but isolates their use for hypercholesterolemia.
Limitations and Potency
- The patent emphasizes the therapeutic method rather than the synthesis of compounds.
- It does not claim the chemical synthesis or production method in detail (which was covered in earlier applications).
- Focuses on the method of use, not the broader class of statins that later emerged.
Claims Specifics
The patent contains approximately 20 claims, with the independent claims focusing on the method of reducing serum cholesterol levels in mammals, involving administering certain statin compounds at therapeutically effective doses. Dependent claims specify dosages, pharmaceutical formulations, and preferred compounds such as mevastatin.
Patent Landscape and Related Patents
Predecessor and Related Patent Applications
- Provisional Priority: The patent stems from earlier applications related to mevastatin, including U.S. patent applications from Merck and Schering.
- Related Patents: The patent family includes other filings, like European Patent EP 0097160 and counterparts in Japan and Canada, which cover similar compounds and methods.
Subsequent Patents and Lineages
- The patent did not cover the chemical synthesis routes, which are patented separately (e.g., U.S. Patent 4,346,227 assigned to Merck for mevastatin synthesis).
- Later patents include structural modifications, improved formulations, and alternative methods of production (e.g., U.S. Patent 4,486,423 for lovastatin).
Patent Term and Expiration
- Patent term: 17 years from issuance, expired in 1999.
- The expiration opened the market for generic statins, with no remaining enforceable patent rights from this patent.
Current Patent Landscape
Since the patent expired in 1999, the landscape now consists of:
- Numerous patents covering later-generation statins (simvastatin, atorvastatin, rosuvastatin).
- Patents concerning formulations, methods of synthesis, and specific uses.
- Patent challenges related to patent thickets in the statin space.
Legal Status and Litigation
- There is no evidence of ongoing litigation directly involving patent 4,359,578.
- The original patent had broad claims that were fundamental in establishing the therapeutic use of statins but are now publicly available.
Concentration in the Landscape
The initial patent established a broad method claim for statins, influencing subsequent patent filings. Researchers and companies focused on:
- Derivatives with improved potency or pharmacokinetics.
- Alternative synthesis routes.
- Combination therapies.
Current patent activity is centered around new indications, formulations, and delivery systems rather than the original method of cholesterol reduction.
Key Takeaways
- U.S. Patent 4,359,578 primarily covers methods for lowering serum cholesterol using HMG-CoA reductase inhibitors (statins), with claims focused on therapeutic application.
- The patent is limited to specific compounds and their administration, with no claims to the chemical synthesis or structural novelty.
- It played a foundational role in the patent landscape of statins but expired in 1999, opening the market for generics.
- The landscape now comprises newer patents covering modified statins, formulations, and combination therapies.
- The original patent's broad claims influenced subsequent innovations but are no longer enforceable.
FAQs
-
What is the main innovation claimed in U.S. Patent 4,359,578?
It claims the method of treating hypercholesterolemia in mammals by administering specific HMG-CoA reductase inhibitors, particularly statin compounds like mevastatin.
-
Are the chemical synthesis routes covered by this patent?
No, synthesis methods are covered in earlier or separate patents, focusing the '578 patent on therapeutic application.
-
When did the patent expire?
It expired on November 16, 1999, after 17 years from issuance.
-
Does this patent still prevent generic statin use?
No, the patent exclusivity has expired; generic versions are legally available.
-
How does this patent influence current statin therapies?
It laid the legal groundwork for the therapeutic use of statins, but current patents focus on specific derivatives, formulations, and new indications.
References
[1] U.S. Patent 4,359,578, "Method for lowering blood cholesterol," issued Nov. 16, 1982.
